HealthDay Reports: Remdesivir Will Not Be Enough to Curb COVID-19, Study Finds
A new study says the antiviral drug on its own won't be enough to significantly curb COVID-19 cases and deaths. There are several dual-drug trials already underway to see if remdesivir paired with another drug could help boost outcomes.
SATURDAY, May 23, 2020 (HealthDay News) -- There have been high hopes that the antiviral drug remdesivir might be an answer to the pandemic of COVID-19. But a major, new study finds the drug on its own won't be enough to significantly curb cases and deaths.
The study, published May 22 in the New England Journal of Medicine, found that, "given high mortality [of patients] despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient."